AMIX Stock Forecast 2025-2026
Distance to AMIX Price Targets
AMIX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Autonomix Medical (AMIX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AMIX and similar high-potential opportunities.
Latest AMIX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, AMIX has a bullish consensus with a median price target of $18.00 (ranging from $18.00 to $18.00). Currently trading at $1.87, the median forecast implies a 862.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMIX Analyst Ratings
AMIX Price Target Range
Latest AMIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 3, 2024 | Ladenburg Thalmann | Buy | Initiates | $1.40 |
Autonomix Medical Inc. (AMIX) Competitors
The following stocks are similar to Autonomix Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Autonomix Medical Inc. (AMIX) Financial Data
Autonomix Medical Inc. has a market capitalization of $4.95M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -662.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Autonomix Medical Inc. (AMIX) Business Model
About Autonomix Medical Inc.
Develops automated medical technology solutions.
The company focuses on creating and commercializing automated systems that enhance the quality and efficiency of medical procedures, particularly in minimally invasive surgeries. It generates revenue through the sale of its innovative solutions and technology integration in healthcare practices.
Autonomix Medical Inc. leverages robotics and software-driven platforms to reduce human error and improve patient outcomes, aligning with global trends toward digital health and automated management. Its role is significant as healthcare systems seek to enhance efficiency and patient care.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
5
CEO
Mr. Bradley Hauser
Country
United States
IPO Year
2024
Website
autonomix.comAutonomix Medical Inc. (AMIX) Latest News & Analysis
Autonomix Medical has expanded its patent portfolio to over 80 issued patents and 40 pending. A new USPTO patent enhances its technology for real-time physiological monitoring in treating nervous system diseases.
Autonomix's expanding patent portfolio enhances its competitive edge, signaling potential for innovative medical solutions. Strong IP protection can lead to increased market value and investor confidence.
Autonomix Medical, Inc. (NASDAQ: AMIX) granted a stock option to purchase 7,500 shares to a new non-executive employee as part of their employment compensation on March 17, 2025.
The grant of stock options to a new employee signals confidence in the company's growth and can influence share price, reflecting potential future performance and market sentiment.
The company has achieved a key milestone by finalizing enhancements to its licensed Apex 6 Radiofrequency Generator with a design lock.
Successful design lock of the Apex 6 RF Generator signals product readiness, potentially boosting sales and market confidence, impacting stock performance positively.
Autonomix will present its catheter-based technology and key findings from an ongoing clinical trial focused on managing pain in pancreatic cancer patients.
Autonomix's presentation on its innovative catheter-based technology and clinical trial results could signal advancements in treatment options, potentially impacting stock performance and market interest.
A clinical trial for a pain treatment related to pancreatic cancer is in progress, with topline data expected in the first half of 2025.
The PoC trial's topline data release in 1H 2025 could significantly impact the company's stock, influencing investor sentiment based on potential treatment efficacy and market opportunity.
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
2 months agoAutonomix Medical, Inc. (NASDAQ: AMIX) released a CEO Corner segment on its website, where CEO Brad Hauser discussed insights from the 43rd Annual J.P. Morgan Healthcare Conference.
Autonomix Medical's CEO update post-conference highlights strategic insights and industry trends, potentially influencing investor sentiment and stock performance in the healthcare sector.
Frequently Asked Questions About AMIX Stock
What is Autonomix Medical Inc.'s (AMIX) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Autonomix Medical Inc. (AMIX) has a median price target of $18.00. The highest price target is $18.00 and the lowest is $18.00.
Is AMIX stock a good investment in 2025?
According to current analyst ratings, AMIX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMIX stock?
Wall Street analysts predict AMIX stock could reach $18.00 in the next 12 months. This represents a 862.6% increase from the current price of $1.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Autonomix Medical Inc.'s business model?
The company focuses on creating and commercializing automated systems that enhance the quality and efficiency of medical procedures, particularly in minimally invasive surgeries. It generates revenue through the sale of its innovative solutions and technology integration in healthcare practices.
What is the highest forecasted price for AMIX Autonomix Medical Inc.?
The highest price target for AMIX is $18.00 from at , which represents a 862.6% increase from the current price of $1.87.
What is the lowest forecasted price for AMIX Autonomix Medical Inc.?
The lowest price target for AMIX is $18.00 from at , which represents a 862.6% increase from the current price of $1.87.
What is the overall AMIX consensus from analysts for Autonomix Medical Inc.?
The overall analyst consensus for AMIX is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are AMIX stock price projections?
Stock price projections, including those for Autonomix Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
